Literature DB >> 21709543

Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis.

D Elias1, C Honoré, F Dumont, M Ducreux, V Boige, D Malka, P Burtin, C Dromain, D Goéré.   

Abstract

PURPOSE: To analyze the impact of systematic second-look surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) performed 1 year after resection of the primary tumor in asymptomatic patients at high risk of developing peritoneal carcinomatosis (PC). PATIENTS AND METHODS: From 1999 to 2009, 41 patients without any sign of recurrence on imaging studies underwent second-look surgery aimed at treating limited PC earlier and more easily. They were selected based on 3 primary tumor-associated criteria: resected minimal synchronous macroscopic PC (n = 25), synchronous ovarian metastases (n = 8), and perforation (n = 8).
RESULTS: PC was found and treated with complete surgery plus HIPEC in 23 of the 41 (56%) patients. The other patients underwent complete abdominal exploration plus systematic HIPEC. Median follow-up was 30 (9-109) months. One patient died postoperatively at day 69. Grade 3-4 morbidity was low (9.7%). The 5-year overall survival rate was 90% and the 5-year disease-free survival rate was 44%. Peritoneal recurrences occurred in 7 patients (17%), 6 of whom had macroscopic PC discovered during the second-look (26%), and one patient had no macroscopic PC (6%). In the univariate analysis, the presence of PC at second-look surgery was a significant risk factor for recurrence (P = 0.006).
CONCLUSION: Selection criteria for high-risk patients appear to be accurate. In these patients, the second-look strategy treated peritoneal carcinomatosis preventively or at an early stage, yielding promising results. This study has allowed us to design a multicentric randomized trial (comparing the second-look + HIPEC approach versus standard follow-up alone), which is beginning.

Entities:  

Mesh:

Year:  2011        PMID: 21709543     DOI: 10.1097/SLA.0b013e31822638f6

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  58 in total

Review 1.  Surgical treatment of peritoneal carcinomatosis: current treatment modalities.

Authors:  Yakup Kulu; Beat Müller-Stich; Markus W Büchler; Alexis Ulrich
Journal:  Langenbecks Arch Surg       Date:  2013-11-19       Impact factor: 3.445

2.  Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases.

Authors:  P Sammartino; S Sibio; D Biacchi; M Cardi; P Mingazzini; M S Rosati; T Cornali; B Sollazzo; J Maherfouad Atta; A Di Giorgio
Journal:  Int J Colorectal Dis       Date:  2014-07-01       Impact factor: 2.571

Review 3.  Management of peritoneal carcinomatosis from colorectal cancer: review of the literature.

Authors:  Carlo Vallicelli; Davide Cavaliere; Fausto Catena; Federico Coccolini; Luca Ansaloni; Elia Poiasina; Hariscine K Abongwa; Belinda De Simone; Laura Alberici; Massimo Framarini; Giorgio M Verdecchia
Journal:  Int J Colorectal Dis       Date:  2014-06-11       Impact factor: 2.571

4.  Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer.

Authors:  Pompiliu Piso; Kathrin Stierstorfer; Michael Gerken; Monika Klinkhammer-Schalke
Journal:  Int J Colorectal Dis       Date:  2018-08-21       Impact factor: 2.571

5.  Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC).

Authors:  Rong-Xin Zhang; Jun-Zhong Lin; Jian Lei; Gong Chen; Li-Ren Li; Zhen-Hai Lu; Pei-Rong Ding; Jiong-Qiang Huang; Ling-Heng Kong; Fu-Long Wang; Cong Li; Wu Jiang; Chuan-Feng Ke; Wen-Hao Zhou; Wen-Hua Fan; Qing Liu; De-Sen Wan; Xiao-Jun Wu; Zhi-Zhong Pan
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-28       Impact factor: 4.553

6.  Safety and efficacy of combined resection of colorectal peritoneal and liver metastases.

Authors:  Stephanie Downs-Canner; Yongli Shuai; Lekshmi Ramalingam; James F Pingpank; Matthew P Holtzman; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  J Surg Res       Date:  2017-06-29       Impact factor: 2.192

7.  Peritoneal carcinomatosis of gastrointestinal tumors: where are we now?

Authors:  Cem Terzi; Naciye Cigdem Arslan; Aras Emre Canda
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 8.  Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Authors:  Paolo Sammartino; Daniele Biacchi; Tommaso Cornali; Maurizio Cardi; Fabio Accarpio; Alessio Impagnatiello; Bianca Maria Sollazzo; Angelo Di Giorgio
Journal:  Indian J Surg Oncol       Date:  2016-01-26

Review 9.  Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer.

Authors:  Aditi Bhatt; Diane Goéré
Journal:  Indian J Surg Oncol       Date:  2016-02-04

10.  Taiwan Society of Colon and Rectal Surgeons (TSCRS) Consensus for Cytoreduction Selection in Metastatic Colorectal Cancer.

Authors:  Chun-Chi Lin; Te-Hung Chen; Yu-Chung Wu; Chuan-Yin Fang; Jaw-Yuan Wang; Chou-Pin Chen; Kai-Wen Huang; Jeng-Kai Jiang
Journal:  Ann Surg Oncol       Date:  2020-09-01       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.